Search results
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Benzinga via Yahoo Finance· 2 years agoThe FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa...
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
Benzinga via Yahoo Finance· 2 years agoAmgen Inc (NASDAQ: AMGN) announced detailed results from the global Phase 3 CodeBreaK 200 trial....
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
Zacks via Yahoo Finance· 1 year agoData from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free...
Why Is Cancer Focused Novocure Stock Trading Higher Today?
Benzinga via Yahoo Finance· 3 months agoNovocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval...
Why Are BeyondSpring Shares Trading Higher?
Benzinga via Yahoo Finance· 1 year agoBeyondSpring Inc (NASDAQ: BYSI) presented data from the lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small...
Merck suffers bad week as 3 Keytruda combination trials fail
BioPharma Dive via Yahoo Finance· 5 months agoThe setbacks for Merck demonstrate the challenge drug developers face in improving on Keytruda,...
Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress
GuruFocus.com via Yahoo Finance· 6 months agoMatinas BioPharma Holdings Inc (MTNB) reported no revenue for Q3 2023 compared to $1.1 million in Q3...
Bristol Myers says KRAS drug succeeds in key trial
BioPharma Dive via Yahoo Finance· 1 month agoConfirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set...
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Benzinga via Yahoo Finance· 2 years agoMerck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy...
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 months agoImage source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2023 Earnings Call Mar 07, 2024, 4:30 p.m. ET Contents: Prepared Remarks Questions and...
